More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC

Affiliations

Comment

Chien-Hao Huang et al. Hepatology. 2023.

. 2023 Sep 1;78(3):706-708.

doi: 10.1097/HEP.0000000000000393. Epub 2023 Apr 5.

¹ Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.

No abstract available

Comment on

Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC.
You M, Gao Y, Fu J, Xie R, Zhu Z, Hong Z, Meng L, Du S, Liu J, Wang FS, Yang P, Chen L. You M, et al. Hepatology. 2023 Sep 1;78(3):943-958. doi: 10.1097/HEP.0000000000000369. Epub 2023 Apr 1. Hepatology. 2023. PMID: 36999652 Free PMC article.

1. Curti BD, Faries MB. Recent advances in the treatment of melanoma. N Engl J Med. 2021;384:2229–2240.
1. Haber PK, Puigvehi M, Castet F, Lourdusamy V, Montal R, Tabrizian P, et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020). Gastroenterology. 2021;161:879–898.
1. Pfister D, Nunez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450–456.
1. Lim CJ, Lee YH, Pan L, Lai L, Chua C, Wasser M, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68:916–927.
1. Cheng Y, Gunasegaran B, Singh HD, Dutertre CA, Loh CY, Lim JQ, et al. Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity. 2021;54:1825–1840 e1827.